Vivos Therapeutics, Inc.

VVOSNASDAQHealthcare● Active

$0.88

+$0.01(+1.38%)

Market Cap$5194557

P/E Ratio—

52W High$7.95

52W Low$0.545

Avg Volume227K

Open$0.91

Beta6.08

Overview

Vivos Therapeutics, Inc. (VVOS) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · VVOS · as of Jun 9, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

∞

Buy/Sell (by trades)

Overall sentiment

BULLISH

↑ Buy 100%Active transactions only · RSU vesting excluded0% Sell ↓

Vivos Therapeutics, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 9, 2026

VVOS insider buying and selling by quarter

VVOS insider selling · VVOS insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

5.4M2.7M0

2022 Q1

2022 Q2

2022 Q4

2023 Q2

2024 Q2

2024 Q4

2025 Q2

2026 Q1

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 9, 2026

Active insiders

Most active in past 12 months · VVOS ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

VVOS executive sell shares · VVOS board member insider trading · VVOS insider trading SEC filing

Showing 16 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Mar 31, 2026	Skaff Michael C 10 percent owner	Purchase	308,848	$1.34	$414K	1,353,625	Form 4
Mar 31, 2026	Skaff Michael C 10 percent owner	Purchase	1,044,777	$1.34	$1.40M⚡	1,044,777	Form 4
Jun 20, 2023	Huntsman Ronald Kirk CEO · Director	Purchase	14,000	$0.53	$7K	86,521	Form 4
Jun 16, 2023	Huntsman Ronald Kirk CEO · Director	Purchase	5,000	$0.53	$3K	72,521	Form 4
Jun 16, 2023	Huntsman Ronald Kirk CEO · Director	Purchase	10,000	$0.54	$5K	67,521	Form 4
Jun 15, 2023	Huntsman Ronald Kirk CEO · Director	Purchase	21	$0.50	$11	57,521	Form 4
Jun 14, 2023	Huntsman Ronald Kirk CEO · Director	Purchase	10,000	$0.49	$5K	57,500	Form 4
Dec 23, 2022	Huntsman Ronald Kirk CEO	Purchase	20,000	$0.50	$10K	47,500	Form 4
May 31, 2022	Huntsman Ronald Kirk CEO	Purchase	8,000	$2.03	$16K	23,500	Form 4
Sep 21, 2021	Huntsman Ronald Kirk CEO · Director	Purchase	5,000	$4.31	$22K	15,500	Form 4
Aug 17, 2021	Huntsman Ronald Kirk CEO · Director	Purchase	5,000	$3.00	$15K	10,500	Form 4
May 25, 2021	Amman Bradford K. CFO	Purchase	1,000	$5.29	$5K	2,000	Form 4
May 25, 2021	Huntsman Ronald Kirk CEO · Director	Purchase	4,000	$5.38	$22K	5,500	Form 4
Dec 24, 2020	Amman Bradford K. CFO	Purchase	1,000	$7.38	$7K	1,000	Form 4
Dec 23, 2020	Huntsman Ronald Kirk CEO · Director	Purchase	1,000	$7.27	$7K	1,500	Form 4
Dec 11, 2020	Huntsman Ronald Kirk CEO · Director	Purchase	500	$8.50	$4K	500	Form 4

Skaff Michael C

10 percent owner

Purchase

Date

Mar 31

308,848

Price

$1.34

Value

$414K

View Form 4 on SEC.gov

Skaff Michael C

10 percent owner

Purchase

Date

Mar 31

1,044,777

Price

$1.34

Value

$1.40M ⚡

View Form 4 on SEC.gov

Huntsman Ronald Kirk

CEO · Director

Purchase

Date

Jun 20

14,000

Price

$0.53

Value

$7K

View Form 4 on SEC.gov

Huntsman Ronald Kirk

CEO · Director

Purchase

Date

Jun 16

5,000

Price

$0.53

Value

$3K

View Form 4 on SEC.gov

Huntsman Ronald Kirk

CEO · Director

Purchase

Date

Jun 16

10,000

Price

$0.54

Value

$5K

View Form 4 on SEC.gov

Huntsman Ronald Kirk

CEO · Director

Purchase

Date

Jun 15

Price

$0.50

Value

$11

View Form 4 on SEC.gov

Huntsman Ronald Kirk

CEO · Director

Purchase

Date

Jun 14

10,000

Price

$0.49

Value

$5K

View Form 4 on SEC.gov

Huntsman Ronald Kirk

CEO

Purchase

Date

Dec 23

20,000

Price

$0.50

Value

$10K

View Form 4 on SEC.gov

Huntsman Ronald Kirk

CEO

Purchase

Date

May 31

8,000

Price

$2.03

Value

$16K

View Form 4 on SEC.gov

Huntsman Ronald Kirk

CEO · Director

Purchase

Date

Sep 21

5,000

Price

$4.31

Value

$22K

View Form 4 on SEC.gov

Huntsman Ronald Kirk

CEO · Director

Purchase

Date

Aug 17

5,000

Price

$3.00

Value

$15K

View Form 4 on SEC.gov

Amman Bradford K.

CFO

Purchase

Date

May 25

1,000

Price

$5.29

Value

$5K

View Form 4 on SEC.gov

Huntsman Ronald Kirk

CEO · Director

Purchase

Date

May 25

4,000

Price

$5.38

Value

$22K

View Form 4 on SEC.gov

Amman Bradford K.

CFO

Purchase

Date

Dec 24

1,000

Price

$7.38

Value

$7K

View Form 4 on SEC.gov

Huntsman Ronald Kirk

CEO · Director

Purchase

Date

Dec 23

1,000

Price

$7.27

Value

$7K

View Form 4 on SEC.gov

Huntsman Ronald Kirk

CEO · Director

Purchase

Date

Dec 11

500

Price

$8.50

Value

$4K

View Form 4 on SEC.gov

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About VVOS insider trading

VVOS insider trades

Vivos Therapeutics, Inc. (VVOS) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Skaff Michael C (10 percent owner). Over the past 12 months, 1 insiders have filed transactions with the SEC. VVOS insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Vivos Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

VVOS insider trading · 5 questions

The insiders of Vivos Therapeutics, Inc. (VVOS) include executives and directors such as Skaff Michael C (10 percent owner), among others. Over the past 12 months, 1 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

VVOS board member insider tradingwho are VVOS insidersVVOS insider rosterVivos Therapeutics, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026